表紙
市場調查報告書
商品編碼
1039101

泌尿道感染(UTI)治療藥的全球市場(2021年∼2025年)

Global Urinary Tract Infection (UTI) Treatment Market 2021-2025

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球泌尿道感染(UTI)治療藥的市場規模在2021年∼2025年的預測期間內,預計將以4.71%的年複合成長率推移,並成長到26億6,000萬美元。

該市場成長的主要因素有泌尿道感染和其他要素的關聯性,泌尿道感染的罹患率上升和院內感染的增加等。

本報告提供全球泌尿道感染(UTI)治療藥市場調查,提供市場概要,市場規模和預測,趨勢,成長要素及課題,客戶形勢,疾病類型·各地區的分析,再加上業者情勢及供應商分析等資訊。

移動向目錄

摘要整理

市場形勢

  • 市場生態系統
  • 價值鏈分析

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2020年年
  • 市場預測:2020年∼2025年的預測

波特的五力分析

  • 買方議價能力
  • 供應商談判力
  • 新加入廠商者的威脅
  • 替代品的威脅
  • 對手企業的威脅
  • 市場的狀況

各疾病類型的市場區隔

  • 市場區隔
  • 各疾病類型比較
  • 單純性UTI:市場規模與預測(2020年∼2025年)
  • 複雜性UTI:市場規模與預測(2020年∼2025年)
  • 各疾病類型的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美: 市場規模和(2020年∼2025年)的預測
  • 歐洲: 市場規模與預測(2020年∼2025年)
  • 亞洲: 市場規模與預測:(2020年∼2025年)
  • 其他地區:市場規模與預測:(2020年∼2025年)
  • 主要國家
  • 各地區形勢的市場機會
  • 市場成長要素
  • 市場課題
  • 市場趨勢

供應商狀況

  • 概要
  • 其他競爭公司狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Pfizer Inc.
  • SHIONOGI Co. Ltd.

附錄

目錄
Product Code: IRTNTR46392

Technavio has been monitoring the urinary tract infection (UTI) treatment market and it is poised to grow by $ 2.66 bn during 2021-2025, progressing at a CAGR of 4.71% during the forecast period. Our report on the urinary tract infection (UTI) treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the relation of UTI with several other factors leading to rising incidence rate of UTI and rising cases of hospital-acquired UTI. In addition, the relation of UTI with several other factors leading to rising incidence rate of UTI is anticipated to boost the growth of the market as well.

The urinary tract infection (UTI) treatment market analysis includes the type segment and geographic landscape.

Technavio's urinary tract infection (UTI) treatment market is segmented as below:

By Type

  • Uncomplicated UTI
  • Complicated UTI

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rising use of urinary cathetersas one of the prime reasons driving the urinary tract infection (UTI) treatment market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on urinary tract infection (UTI) treatment market covers the following areas:

  • Urinary tract infection (UTI) treatment market sizing
  • Urinary tract infection (UTI) treatment market forecast
  • Urinary tract infection (UTI) treatment market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading urinary tract infection (UTI) treatment market vendors that include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., and SHIONOGI Co. Ltd. Also, the urinary tract infection (UTI) treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Disease type
    • Market segments
    • Comparison by Disease type
    • Uncomplicated UTI - Market size and forecast 2020-2025
    • Complicated UTI - Market size and forecast 2020-2025
    • Market opportunity by Disease type
  • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity By Geographical Landscape
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Overview
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Abbott Laboratories
    • AbbVie Inc.
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH
    • Cipla Inc.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Merck and Co. Inc.
    • Pfizer Inc.
    • SHIONOGI Co. Ltd.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Disease type - Market share 2020-2025 (%)
  • 22: Comparison by Disease type
  • 23: Uncomplicated UTI - Market size and forecast 2020-2025 ($ million)
  • 24: Uncomplicated UTI - Year-over-year growth 2020-2025 (%)
  • 25: Complicated UTI - Market size and forecast 2020-2025 ($ million)
  • 26: Complicated UTI - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Disease type
  • 28: Customer landscape
  • 29: Market share By Geographical Landscape 2020-2025 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2020-2025 ($ million)
  • 32: North America - Year-over-year growth 2020-2025 (%)
  • 33: Europe - Market size and forecast 2020-2025 ($ million)
  • 34: Europe - Year-over-year growth 2020-2025 (%)
  • 35: Asia - Market size and forecast 2020-2025 ($ million)
  • 36: Asia - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ million)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity By Geographical Landscape ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Abbott Laboratories - Overview
  • 48: Abbott Laboratories - Business segments
  • 49: Abbott Laboratories - Key offerings
  • 50: Abbott Laboratories - Key customers
  • 51: Abbott Laboratories - Segment focus
  • 52: AbbVie Inc. - Overview
  • 53: AbbVie Inc. - Product and service
  • 54: AbbVie Inc. - Key offerings
  • 55: AbbVie Inc. - Key customers
  • 56: AbbVie Inc. - Segment focus
  • 57: AstraZeneca Plc - Overview
  • 58: AstraZeneca Plc - Product and service
  • 59: AstraZeneca Plc - Key offerings
  • 60: AstraZeneca Plc - Key customers
  • 61: AstraZeneca Plc - Segment focus
  • 62: Boehringer Ingelheim International GmbH - Overview
  • 63: Boehringer Ingelheim International GmbH - Business segments
  • 64: Boehringer Ingelheim International GmbH - Key offerings
  • 65: Boehringer Ingelheim International GmbH - Key customers
  • 66: Boehringer Ingelheim International GmbH - Segment focus
  • 67: Cipla Inc. - Overview
  • 68: Cipla Inc. - Business segments
  • 69: Cipla Inc. - Key offerings
  • 70: Cipla Inc. - Key customers
  • 71: Cipla Inc. - Segment focus
  • 72: F. Hoffmann-La Roche Ltd. - Overview
  • 73: F. Hoffmann-La Roche Ltd. - Business segments
  • 74: F. Hoffmann-La Roche Ltd. - Key offerings
  • 75: F. Hoffmann-La Roche Ltd. - Key customers
  • 76: F. Hoffmann-La Roche Ltd. - Segment focus
  • 77: GlaxoSmithKline Plc - Overview
  • 78: GlaxoSmithKline Plc - Business segments
  • 79: GlaxoSmithKline Plc - Key offerings
  • 80: GlaxoSmithKline Plc - Key customers
  • 81: GlaxoSmithKline Plc - Segment focus
  • 82: Merck and Co. Inc. - Overview
  • 83: Merck and Co. Inc. - Business segments
  • 84: Merck and Co. Inc. - Key offerings
  • 85: Merck and Co. Inc. - Key customers
  • 86: Merck and Co. Inc. - Segment focus
  • 87: Pfizer Inc. - Overview
  • 88: Pfizer Inc. - Business segments
  • 89: Pfizer Inc. - Key offerings
  • 90: Pfizer Inc. - Key customers
  • 91: Pfizer Inc. - Segment focus
  • 92: SHIONOGI Co. Ltd. - Overview
  • 93: SHIONOGI Co. Ltd. - Business segments
  • 94: SHIONOGI Co. Ltd. - Key offerings
  • 95: SHIONOGI Co. Ltd. - Key customers
  • 96: SHIONOGI Co. Ltd. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations